Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

In obesity and insulin resistance ... mechanism of PKC activation is through ligand binding to G-protein-coupled receptors, which for example occurs during α-adrenergic stimulation.

Tyrosine-protein phosphatase non-receptor type 1 (PTP1B) acts as a negative regulator of the insulin signaling pathway by dephosphorylating both the insulin receptor (IR) and the insulin receptor ...

Insulin receptors are widely expressed and distributed across the brain and are mainly the insulin receptor-A isoform rather ...

Understanding the molecular mechanisms of insulin resistance remains a major medical challenge of the twenty-first century. Over the last half-century, many hypotheses have been proposed to ...

A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Average price per insulin unit dropped 42%, from $0.33 in 2019 to $0.19 in mid-2024 -- the lowest average recorded in a ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...